Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Date:2016-02-05Source: AmoyDx
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection kit: EGFR/ALK/ROS1 panel detecting 18 EGFR mutations, 5 ALK fusions and 9 ROS1 fusions simultaneously. The highly sensitive assay uses one step real-time PCR (combined reverse transcription and PCR amplification technology) to analyze EGFR, ALK, and ROS1 gene status in human NSCLC (non-small cell lung cancer) tissue samples. The kit also got CE-mark in Europe.
Recommend
AmoyDx® PD-L1 (E1L3N) assay gained the priority recommendation from Chinese expert consensus
21 /02
AmoyDx has successfully held the 2023 Distributors Annual Meeting at the headquarter in Xiamen, China, on January 22-23, 2024
06 /02
Highlights of China International Import Expo (CIIE) 2023 - Amoy Diagnostics Announced Multiple Collaborations with AstraZeneca and Pfizer
13 /11
AmoyDx® Microsatellite Instability (MSI) Detection Kit Received NMPA Approval for Pan-Tumor Immunotherapy Companion Diagnostics
03 /11
AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China
15 /08